|Description||Uprosertib, also known as GSK2141795 and GSK795, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.|
|B0084-462537||25 mg||$298||In stock|
|Appearance||white solid powder|
|Synonyms||GSK-2141795; GSK2141795; GSK 2141795; GSK795; GSK-795; GSK 795. Uprosertib.|
CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine co...
A-443654 is a potent small-molecule inhibitor of all three Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines test...
A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
Akt/SKG Substrate Peptide
Akt/SKG Substrate Peptide is a synthetic peptide and used as a substrate for Akt/PKB. It could not be phosphorylated by MAP kinase or p70 S6 kinase activated pr...
FPA 124 is an Akt/PKB inhibitor (IC50 = 100 nM) that inhibits cell proliferation in various cancer cell lines in vitro and decreases NF-κB activity and tumor lo...
MK-2206 is a highly selective Akt inhibitor with IC50 of 8 nM, 12 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. It is undergoing a phase II clinical trial...
MK-2206 hydrochloride is the hydrochloride form of MK-2206, which is an allosteric inhibitor of Akt and an orally bioavailable allosteric inhibitor of the serin...